Rossari Biotech Ltd - May 2025 Earnings Call Transcript Analysis
·
1 min read
Earnings Call Transcript Analysis Report
#
Key Financial Metrics (FY25 vs FY24)
#
Revenue from Operations
#
- Rs. 2,080 crore, up 13.6% YoY. (Crossed Rs. 2,000 crore milestone).
- “For the full year FY25, we crossed the Rs. 2,000 crore milestone with revenue from operations reaching Rs. 2,080 crore, up 13.6% YoY.”
EBITDA
#
- Rs. 265.1 crore, up 6.1% YoY.
EBITDA Margin (Consolidated)
#
- 12.7% (down from 13.6% in FY24).
- “EBITDA increased by 6.1% to Rs. 265.1 crore with an EBITDA margin of 12.7% compared to 13.6% in FY24.”
Core Business Adjusted EBITDA Margin (FY25)
#
- Approximately 15%.
- “…our core business continues to deliver healthy profitability with an adjusted EBITDA range of approximately 15% for FY25.”